CALGB 50801: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Aims: The purpose of this study is to determine if it is possible to safely reduce the total number of cycles of chemotherapy needed for Hodgkin lymphoma based on the patient's response during treatment as seen on positron emission tomography (PET) scan images. A PET scan is an imaging technique that can detect the possibility of active cancer.
Diagnosis: Bulky Stage I and II Classical Hodgkin Lymphoma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH11-030
Sponsor: Alliance
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E2905: Randomized Phase III Trial Comparing The Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlemid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.
Aims: The purpose of this study is to compare the good and/or bad affects of a drug called lenalidomide on blood disorders when given alone or in combination with a drug called epoetin alfa. Epoetin alfa boosts the production of red blood cells. The drug lenalidomide makes young red blood cells more likely to be affected by the growth-promoting effects of epoetin alfa. This study aims to determine if the combination of treatment with epoetin alfa and lenalidomide is better than lenalidomide alone in improving red blood cell production and decreasing the need for blood transfusions in patients with MDS (myelodysplastic syndrome).
Diagnosis: Myelodysplastic Syndrome or Symptomatic Anemia
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH09-422
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

INCB-MA-PV-401: Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practicies (REVEAL)
Aims: This is a prospective, observational study of pateints with Polycythemia Vera. The purpose of this study is to find out more information about people with PV, follow the course of the disease in these people, and find out how the disease and standard medical care affect the daily life of people being treated for PV.
Diagnosis: Polycythemia Vera
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH05EH15-021
Sponsor: Incyte Corporation
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumuamb, Bortezomib (NSC #681239, IND#58443) and Bendamustine in Patients with Untreated Follicular Lymphoma
Aims: The purpose of this study is to compare the effects of treatment with a combination of the drugs ofatumumab and bendamustine against treatment with a combination of the drugs ofatumumab, bendamustine, and bortezomib in patients with follicular lymphoma.  The combination of these drugs has not been approved for use in follicular lymphoma by the FDA.  However, these drugs are FDA-approved for certain types of cancers when used individually.
Diagnosis: Follicular Lymphoma
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH12-075
Sponsor: Alliance
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

S1001: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Aims: The purpose of this study is to give more intensive treatment to patients whose PET/CT scan shows that they are at a greater chance of still having active lymphoma and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma. IN this way, we hope to improve the cure rate for all patients while decreasing the side effects of treatment.
Diagnosis: Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH13-343
Sponsor: Southwest Oncology Group (SWOG)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Celgene Connect MM: The Multiple Myeloma Disease Registry
Aims: This research study is being done to learn more about multiple myeoma and its treatments. Researchers also want to better understand how multiple myeloma impacts the life of people living with multiple myeloma. This is an observational study, which means it is a study that does not prescibe research medication or require medical treatment. The purpose of this study is to collect information on your disease and medical treatment that your doctor is already collecting as part of your normal care.
Diagnosis: Multiple Myeloma (MM)
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH10-273
Sponsor: Celgene
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Celgene Connect MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Aims: There are three main purposes of this study: 1. To use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression and survival. 2. To use the information to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. 3. To use results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.
Diagnosis: Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-390
Sponsor: Celgene
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Aims:The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and Ibrutinib have on you and your CLL. The first three of these drugs are standard treatments for CLL. Fludarabine and cyclophosphamide have been approved by the Food and Drug Administration (FDA) for the treatment of CLL. Rituximab is approved for the treatment of CLL when given in combination with fludarabine and cyclophosphamide and is also approved for treatment of non-Hodgkin lymphoma and rheumatoid arthritis. Ibrutinib has been previously studied in patients with CLL, and has been approved by the FDA for use in previously treated CLL patients. In this study, ibrutinib is investigational because it will be given to previously untreated CLL patients and administered in combination with rituximab. This research is being done because currently there is no proven cure for this type of cancer.
Diagnosis: Chronic Lymphocytic Leukemia (CLL)
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH15-110C
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Aims: The purpose of this study is to compare the effects, good and/or bad, the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This investigational drug will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinotumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.
Diagnosis: BRCA/ABL negative Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-299
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CIBMTR: Protocol for Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries 
Aims: The purpose of this study is to collect information on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-249
Sponsor: National Marrow Donor Program
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC14-0899: Phase II Randomized Trial of Continuation of Post-Transplant Maintainence with Single-Agent Lenalidomide vs. Consolidation /Maintainence with Izaxomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma
Aims: The purpose of this study is to collect information on the combination of three treatments (Izaxomib-Lenalidomide and Dexamethasone)on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Jagoda Jasielec, MD 
IRB Approval Number: EH16-051
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

TG Therapeutics: UTX-IB-301A Phase 3 Randomized Study to Assess teh Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib  Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Aims: The purpose of this study is collect information about how effective the combination of the investigational drug, ublituximab,  is with the FDA approved drug, Ibrutinib.
Diagnosis: Chronic Lymphocytic Leukemia
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-228
Sponsor: TG Therapeutics, Inc 
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes